SEARCH BY
| Category | Company |
|---|---|
| Founded | 1849 |
| Sector | Life Science |
| Employees | 81,000 |
| Revenue | 63.6B USD (2024) |
Pfizer is a global pharmaceutical company that is involved in the discovery, development, manufacture, and marketing of a wide range of healthcare products, including medicines and vaccines. The company's portfolio includes treatments across a broad spectrum of areas such as oncology, cardiology, neurology, and infectious diseases, among others. Pfizer was founded in 1849 and is based in New York, New York.
| DEAL STATS | # |
|---|---|
| Overall | 45 of 46 |
| Sector: Medical Products M&A | 2 of 2 |
| Type: Special Situations/Distressed M&A Deals | 1 of 1 |
| State: California M&A | 14 of 14 |
| Country: United States M&A | 32 of 33 |
| Year: 2023 M&A | 2 of 2 |
| Size (of disclosed) | 24 of 24 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2023-03-13 |
Seagen
Bothell, Washington, United States Seagen is a biotechnology company provides an antibody-drug conjugate (ADC) technology harnesses the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. Seattle Genetics commercializes ADCETRIS (brentuximab vedotin) for the treatment of several types of CD30-expressing lymphomas. Seattle was founded in 1997 and is based in Bothell, Washington. |
Buy | $43.0B |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2025-09-22 |
Metsera
New York, New York, United States Metsera is a clinical-stage biopharmaceutical company accelerating medicines for obesity and metabolic diseases. The company is advancing a broad portfolio of oral and injectable incretin, non-incretin, and combination therapies with potential best-in-class profiles to address multiple therapeutic targets and meet the future needs of a rapidly evolving weight loss treatment landscape. Metsera was founded in 2022 and is based in New York City. |
Buy | $4.9B |
